{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T06:44:24Z","timestamp":1751006664336,"version":"3.41.0"},"reference-count":95,"publisher":"Jaypee Brothers Medical Publishing","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.59556\/japi.72.0780","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T06:51:43Z","timestamp":1750661503000},"page":"59-72","source":"Crossref","is-referenced-by-count":1,"title":["Olmesartan: 360-degree Perspectives Befitting an Angiotensin Receptor Blocker"],"prefix":"10.59556","volume":"72","author":[{"given":"Sadanand","family":"Shetty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Bhoraskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyanarayan","family":"Routray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Sreenivasamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Kumar","family":"Shrivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anooja","family":"Jose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charmy","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Qamra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parthasarathy","family":"Muralidharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"issue":"(7):","key":"key20250623065138_B1","doi-asserted-by":"crossref","first-page":"474\u2013","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).","volume":"11","author":"Anjana","year":"2023;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(4):","key":"key20250623065138_B2","doi-asserted-by":"crossref","first-page":"565\u2013","DOI":"10.1016\/j.ihj.2018.02.003","article-title":"Hypertension: the most important non communicable disease risk factor in India.","volume":"70","author":"Gupta","year":"2018;","journal-title":"Indian Heart J"},{"issue":"(9349):","key":"key20250623065138_B3","first-page":"1903\u2013","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.","volume":"360","author":"Lewington","year":"2002;","journal-title":"Lancet"},{"issue":"(5):","key":"key20250623065138_B4","doi-asserted-by":"crossref","first-page":"519\u2013","DOI":"10.1016\/j.nefroe.2021.10.008","article-title":"Hypertension mediated kidney and cardiovascular damage and risk stratification: redefining concepts.","volume":"42","author":"M\u00e1rquez","year":"2022;","journal-title":"Nefrologia (Engl Ed)"},{"issue":"(9587):","key":"key20250623065138_B5","doi-asserted-by":"crossref","first-page":"591\u2013","DOI":"10.1016\/S0140-6736(07)61299-9","article-title":"Essential hypertension.","volume":"370","author":"Messerli","year":"2007;","journal-title":"Lancet"},{"issue":"(3):","key":"key20250623065138_B6","first-page":"114\u2013","article-title":"Blood pressure control and cardiovascular risk reduction.","volume":"11","author":"Antonakoudis","year":"2007;","journal-title":"Hippokratia"},{"issue":"(3):","key":"key20250623065138_B7","doi-asserted-by":"crossref","first-page":"505\u2013","DOI":"10.1161\/HYPERTENSIONAHA.121.18502","article-title":"Hypertension-mediated organ damage: prevalence, correlates, and prognosis in the community.","volume":"79","author":"Vasan","year":"2022;","journal-title":"Hypertension"},{"issue":"(12):","key":"key20250623065138_B8","doi-asserted-by":"crossref","first-page":"1874\u2013","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).","volume":"41","author":"Mancia","year":"2023;","journal-title":"J Hypertens"},{"issue":"(6):","key":"key20250623065138_B9","doi-asserted-by":"crossref","first-page":"1334\u2013","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines.","volume":"75","author":"Unger","year":"2020;","journal-title":"Hypertension"},{"issue":"(11):","key":"key20250623065138_B10","doi-asserted-by":"crossref","first-page":"745\u2013","DOI":"10.1038\/s41371-020-0349-x","article-title":"Indian guidelines on hypertension-IV (2019).","volume":"34","author":"Shah","year":"2020;","journal-title":"J Hum Hypertens"},{"issue":"(6):","key":"key20250623065138_B11","doi-asserted-by":"crossref","first-page":"1269\u2013","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"71","author":"Whelton","year":"2018;","journal-title":"Hypertension"},{"issue":"(6):","key":"key20250623065138_B12","doi-asserted-by":"crossref","first-page":"e12471.","DOI":"10.1111\/1755-5922.12471","article-title":"Management of arterial hypertension with angiotensin receptor blockers: current evidence and the role of olmesartan.","volume":"36","author":"Omboni","year":"2018;","journal-title":"Cardiovasc Ther"},{"issue":"(2):","key":"key20250623065138_B13","doi-asserted-by":"crossref","first-page":"174\u2013","DOI":"10.1053\/j.ajkd.2020.01.007","article-title":"CKD awareness among US adults by future risk of kidney failure.","volume":"76","author":"Chu","year":"2020;","journal-title":"Am J Kidney Dis"},{"issue":"(4):","key":"key20250623065138_B14","doi-asserted-by":"crossref","first-page":"255\u2013","DOI":"10.1007\/s40256-016-0165-4","article-title":"The different therapeutic choices with ARBs. Which one to give? When? Why?","volume":"16","author":"D\u00e9zsi","year":"2016;","journal-title":"Am J Cardiovasc Drugs"},{"key":"key20250623065138_B15","first-page":"1\u2013","article-title":"Hypertension: focus on olmesartan medoxomil.","volume":"1:","author":"Bell","year":"2009;","journal-title":"Clin Med Ther"},{"issue":"(1):","key":"key20250623065138_B16","doi-asserted-by":"crossref","first-page":"13\u2013","DOI":"10.1007\/s40119-017-0087-5","article-title":"Management of hypertension using olmesartan alone or in combination.","volume":"6","author":"Zhang","year":"2017;","journal-title":"Cardiol Ther"},{"issue":"(1):","key":"key20250623065138_B17","first-page":"22\u2013","article-title":"Use of angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.","volume":"36","author":"Munger","year":"2011;","journal-title":"P T"},{"issue":"(4):","key":"key20250623065138_B18","doi-asserted-by":"crossref","first-page":"327\u2013","DOI":"10.2147\/vhrm.2006.2.4.327","article-title":"Olmesartan medoxomil: current status of its use in monotherapy.","volume":"2","author":"Brunner","year":"2006;","journal-title":"Vasc Health Risk Manag"},{"issue":"(4):","key":"key20250623065138_B19","doi-asserted-by":"crossref","first-page":"185\u2013","DOI":"10.2165\/00044011-200626040-00002","article-title":"Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.","volume":"26","author":"Brunner","year":"2006;","journal-title":"Clin Drug Investig"},{"issue":"(3):","key":"key20250623065138_B20","doi-asserted-by":"crossref","first-page":"135\u2013","DOI":"10.1097\/01.mbp.0000209087.40117.b3","article-title":"Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.","volume":"11","author":"Chrysant","year":"2006;","journal-title":"Blood Press Monit"},{"issue":"(Suppl 5):","key":"key20250623065138_B21","doi-asserted-by":"crossref","first-page":"S26\u2013","DOI":"10.1097\/00005344-199423005-00006","article-title":"FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. United States Food and Drug Administration.","volume":"23","author":"Meredith","year":"1994;","journal-title":"J Cardiovasc Pharmacol"},{"issue":"(5):","key":"key20250623065138_B22","doi-asserted-by":"crossref","first-page":"325\u2013","DOI":"10.1111\/j.1524-6175.2002.01051.x","article-title":"Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.","volume":"4","author":"Neutel","year":"2002;","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"(1):","key":"key20250623065138_B23","doi-asserted-by":"crossref","first-page":"7\u2013","DOI":"10.1291\/hypres.31.7","article-title":"Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.","volume":"31","author":"Nakayama","year":"2008;","journal-title":"Hypertens Res"},{"key":"key20250623065138_B24","first-page":"21\u2013","article-title":"Comparative efficacy of olmesartan and perindopril on the effect on central blood pressure and elastic properties of the arteries in patients with mild to moderate hypertension.","volume":"31:","author":"Sirenko","year":"2022;","journal-title":"Hypertension"},{"issue":"(8):","key":"key20250623065138_B25","first-page":"66\u2013","article-title":"Effectiveness of olmesartan on blood pressure control in hypertensive patients in India: a real world, retrospective, observational study from Electronic Medical Records.","volume":"68","author":"Khan","year":"2020;","journal-title":"J Assoc Physicians India"},{"issue":"(3):","key":"key20250623065138_B26","first-page":"106\u2013","article-title":"Efficacy and tolerability of olmesartan, telmisartan, and losartan in patients of stage I hypertension: a randomized, open-label study.","volume":"8","author":"Kalikar","year":"2017;","journal-title":"J Pharmacol Pharmacother"},{"key":"key20250623065138_B27","doi-asserted-by":"crossref","first-page":"219\u2013","DOI":"10.2147\/DDDT.S53253","article-title":"Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.","volume":"8:","author":"Daikuhara","year":"2014;","journal-title":"Drug Des Devel Ther"},{"issue":"(3):","key":"key20250623065138_B28","doi-asserted-by":"crossref","first-page":"340\u2013","DOI":"10.1016\/j.ihj.2014.05.002","article-title":"WIN OVER study: efficacy and safety of olmesartan in Indian hypertensive patients: results of an open label, non-comparative, multi-centric, post marketing observational study.","volume":"66","author":"Kumbla","year":"2014;","journal-title":"Indian Heart J"},{"key":"key20250623065138_B29","doi-asserted-by":"crossref","first-page":"62\u2013","DOI":"10.1016\/j.curtheres.2013.02.002","article-title":"Olmesartan is more effective than other angiotensin receptor antagonists in reducing proteinuria in patients with chronic kidney disease other than diabetic nephropathy.","volume":"74:","author":"Ono","year":"2013;","journal-title":"Curr Ther Res Clin Exp"},{"issue":"(19):","key":"key20250623065138_B30","first-page":"726\u2013","article-title":"Effect of olmesartan medoxomil on arterial stiffness in patients with essential hypertension. Med Clin (Barc)","volume":"128","author":"Mediavilla Garc\u00eda","year":"2007;"},{"issue":"(6):","key":"key20250623065138_B31","doi-asserted-by":"crossref","first-page":"1273\u2013","DOI":"10.1111\/j.1476-5381.2010.00750.x","article-title":"Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.","volume":"160","author":"Ma","year":"2010;","journal-title":"Br J Pharmacol"},{"issue":"(6):","key":"key20250623065138_B32","doi-asserted-by":"crossref","first-page":"363\u2013","DOI":"10.2165\/00129784-200606060-00002","article-title":"Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.","volume":"6","author":"Takai","year":"2006;","journal-title":"Am J Cardiovasc Drugs"},{"issue":"(10):","key":"key20250623065138_B33","doi-asserted-by":"crossref","first-page":"1521\u2013","DOI":"10.1097\/HJH.0000000000003503","article-title":"The importance of microvascular inflammation in ageing and age-related diseases: a position paper from the ESH working group on small arteries, section of microvascular inflammation.","volume":"41","author":"Mengozzi","year":"2023;","journal-title":"J Hypertens"},{"key":"key20250623065138_B34","doi-asserted-by":"crossref","first-page":"1058.","DOI":"10.3389\/fimmu.2017.01058","article-title":"Inflammatory markers for arterial stiffness in cardiovascular diseases.","volume":"8:","author":"Mozos","year":"2017;","journal-title":"Front Immunol"},{"issue":"(2):","key":"key20250623065138_B35","doi-asserted-by":"crossref","first-page":"178\u2013","DOI":"10.1007\/s00380-013-0343-0","article-title":"Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.","volume":"29","author":"Miyoshi","year":"2014;","journal-title":"Heart Vessels"},{"issue":"(4):","key":"key20250623065138_B36","doi-asserted-by":"crossref","first-page":"408\u2013","DOI":"10.1007\/s00380-010-0060-x","article-title":"Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients.","volume":"26","author":"Miyoshi","year":"2011;","journal-title":"Heart Vessels"},{"issue":"(9):","key":"key20250623065138_B37","doi-asserted-by":"crossref","first-page":"1103\u2013","DOI":"10.1161\/01.CIR.0000140265.21608.8E","article-title":"Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.","volume":"110","author":"Fliser","year":"2004;","journal-title":"Circulation"},{"key":"key20250623065138_B38","unstructured":"Bornstein AB, Rao SS, Marwaha K. Left Ventricular Hypertrophy. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557534\/. Accessed on 27 Aug 2024"},{"issue":"(6):","key":"key20250623065138_B39","doi-asserted-by":"crossref","first-page":"343\u2013","DOI":"10.1038\/jhh.2011.104","article-title":"Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies.","volume":"26","author":"Cuspidi","year":"2012;","journal-title":"J Hum Hypertens"},{"issue":"(5):","key":"key20250623065138_B40","doi-asserted-by":"crossref","first-page":"639\u2013","DOI":"10.1185\/030079904125003449","article-title":"Left ventricular hypertrophy in hypertensive patients in Indian primary care: prevalence and effect of treatment with sustained release indapamide.","volume":"20","author":"Lokhandwala","year":"2004;","journal-title":"Curr Med Res Opin"},{"issue":"(12):","key":"key20250623065138_B41","doi-asserted-by":"crossref","first-page":"2175\u2013","DOI":"10.1111\/jch.14047","article-title":"Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: a network meta-analysis of randomized controlled trials.","volume":"22","author":"Chen","year":"2020;","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"(Suppl 2):","key":"key20250623065138_B42","doi-asserted-by":"crossref","first-page":"ehaa946.2775.","DOI":"10.1093\/ehjci\/ehaa946.2775","article-title":"Olmesartan improves left ventricular hypertrophy in patients with hypertension and type 2 diabetes with low angiotensin-(1-7) blood levels.","volume":"41","author":"Yushko","year":"2020;","journal-title":"Eur Heart J"},{"issue":"(2):","key":"key20250623065138_B43","doi-asserted-by":"crossref","first-page":"118\u2013","DOI":"10.1038\/hr.2009.192","article-title":"Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.","volume":"33","author":"Tsutamoto","year":"2010;","journal-title":"Hypertens Res"},{"issue":"(4):","key":"key20250623065138_B44","doi-asserted-by":"crossref","first-page":"187\u2013","DOI":"10.1080\/08037050903047236","article-title":"Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function.","volume":"18","author":"Albayrak","year":"2009;","journal-title":"Blood Press"},{"key":"key20250623065138_B45","doi-asserted-by":"crossref","first-page":"155\u2013","DOI":"10.1016\/B978-0-12-801364-9.00021-3","article-title":"Angiotensin-(1-7) and Mas: A Brief History.","author":"Alenina","year":"2015:","journal-title":"The Protective Arm of the Renin Angiotensin System (RAS)."},{"issue":"(6):","key":"key20250623065138_B46","doi-asserted-by":"crossref","first-page":"1246\u2013","DOI":"10.1161\/hy1201.101214","article-title":"History about the discovery of the renin-angiotensin system.","volume":"38","author":"Basso","year":"2001;","journal-title":"Hypertension"},{"issue":"(4):","key":"key20250623065138_B47","doi-asserted-by":"crossref","first-page":"815\u2013","DOI":"10.1016\/j.kint.2019.05.028","article-title":"Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?","volume":"96","author":"Marquez","year":"2019;","journal-title":"Kidney Int"},{"issue":"(6):","key":"key20250623065138_B48","doi-asserted-by":"crossref","first-page":"1138\u2013","DOI":"10.1161\/HYPERTENSIONAHA.113.01274","article-title":"Angiotensin-(1-7).","volume":"63","author":"Santos","year":"2014;","journal-title":"Hypertension"},{"key":"key20250623065138_B49","doi-asserted-by":"crossref","first-page":"620990.","DOI":"10.3389\/fmed.2021.620990","article-title":"Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2(ACE2) Inhibition for the Treatment of COVID-19.","volume":"8:","author":"Issa","year":"2021;","journal-title":"Front Med"},{"issue":"(1):","key":"key20250623065138_B50","doi-asserted-by":"crossref","first-page":"43.","DOI":"10.1186\/s13098-023-00987-1","article-title":"Effect of olmesartan and amlodipine on serum angiotensin-(1-7) levels and kidney and vascular function in patients with type 2 diabetes and hypertension.","volume":"15","author":"Kim","year":"2023;","journal-title":"Diabetol Metab Syndr"},{"issue":"(5):","key":"key20250623065138_B51","doi-asserted-by":"crossref","first-page":"667\u2013","DOI":"10.1016\/j.hlc.2018.06.1057","article-title":"Markers of atherosclerosis: part 1 - serological markers.","volume":"28","author":"Tibaut","year":"2019;","journal-title":"Heart Lung Circ"},{"issue":"(2):","key":"key20250623065138_B52","doi-asserted-by":"crossref","first-page":"e030131.","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease.","volume":"13","author":"Barzilay","year":"2024;","journal-title":"J Am Heart Assoc"},{"issue":"(3):","key":"key20250623065138_B53","first-page":"105\u2013","article-title":"Microalbuminuria, is it so important?","volume":"11","author":"Koroshi","year":"2007;","journal-title":"Hippokratia"},{"issue":"(3):","key":"key20250623065138_B54","first-page":"429\u2013","article-title":"Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: a randomized controlled trial.","volume":"20","author":"Agha","year":"2009;","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"key20250623065138_B55","unstructured":"Ruilope L, Cerezo C. Albuminuria under renin-angiotensin system suppression. e-Journal of Cardiology Practice. 2012;10(15). https:\/\/www.escardio.org\/Journals\/E-Journal-of-Cardiology-Practice\/Volume-10\/Albuminuria-under-renin-angiotensin-system-suppression. Accessed 27 Aug 2024."},{"issue":"(3):","key":"key20250623065138_B56","doi-asserted-by":"crossref","first-page":"381\u2013","DOI":"10.1159\/000112270","article-title":"Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease.","volume":"28","author":"Palmer","year":"2008;","journal-title":"Am J Nephrol"},{"issue":"(10):","key":"key20250623065138_B57","doi-asserted-by":"crossref","first-page":"907\u2013","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.","volume":"364","author":"Haller","year":"2011;","journal-title":"N Engl J Med"},{"issue":"(1):","key":"key20250623065138_B58","doi-asserted-by":"crossref","first-page":"16\u2013","DOI":"10.1111\/jch.13425","article-title":"Cardio-ankle vascular index and cardiovascular disease: Systematic review and meta-analysis of prospective and cross-sectional studies.","volume":"21","author":"Matsushita","year":"2019;","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"(6):","key":"key20250623065138_B59","doi-asserted-by":"crossref","first-page":"1570\u2013","DOI":"10.1038\/s41440-024-01637-3","article-title":"Is uric acid a causal risk factor of arterial stiffness in patients with hypertension?","volume":"47","author":"Maruhashi","year":"2024;","journal-title":"Hypertens Res"},{"key":"key20250623065138_B60","first-page":"8887248.","article-title":"The role of angiotensin antagonism in coronary plaque regression: insights from the Glagovian model.","volume":"2021:","author":"Alkatiri","year":"2021;","journal-title":"Int J Vasc Med"},{"issue":"(5):","key":"key20250623065138_B61","doi-asserted-by":"crossref","first-page":"1063\u2013","DOI":"10.1161\/ATVBAHA.120.313130","article-title":"Uses of arterial stiffness in clinical practice.","volume":"40","author":"Wilkinson","year":"2020;","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"(1):","key":"key20250623065138_B62","first-page":"43\u2013","article-title":"Is augmentation index a good measure of vascular stiffness in the elderly?","volume":"36","author":"Fantin","year":"2007;","journal-title":"Age Ageing"},{"issue":"(2):","key":"key20250623065138_B63","doi-asserted-by":"crossref","first-page":"98\u2013","DOI":"10.1111\/jch.12458","article-title":"Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome.","volume":"17","author":"Raff","year":"2015;","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"(4):","key":"key20250623065138_B64","doi-asserted-by":"crossref","first-page":"709\u2013","DOI":"10.1161\/HYPERTENSIONAHA.114.03282","article-title":"Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome.","volume":"64","author":"Laurent","year":"2014;","journal-title":"Hypertension"},{"issue":"(1):","key":"key20250623065138_B65","doi-asserted-by":"crossref","first-page":"134\u2013","DOI":"10.1016\/j.atherosclerosis.2011.10.013","article-title":"Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial.","volume":"220","author":"Hirohata","year":"2012;","journal-title":"Atherosclerosis"},{"issue":"(10):","key":"key20250623065138_B66","doi-asserted-by":"crossref","first-page":"976\u2013","DOI":"10.1016\/j.jacc.2009.09.062","article-title":"Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.","volume":"55","author":"Hirohata","year":"2010;","journal-title":"J Am Coll Cardiol"},{"issue":"(5):","key":"key20250623065138_B67","doi-asserted-by":"crossref","first-page":"621\u2013","DOI":"10.5551\/jat.497","article-title":"Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.","volume":"16","author":"Miyashita","year":"2009;","journal-title":"J Atheroscler Thromb"},{"issue":"(2):","key":"key20250623065138_B68","doi-asserted-by":"crossref","first-page":"97\u2013","DOI":"10.1177\/1753944707085982","article-title":"Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.","volume":"1","author":"Stumpe","year":"2007;","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"(3):","key":"key20250623065138_B69","doi-asserted-by":"crossref","first-page":"165\u2013","DOI":"10.1016\/j.jash.2007.11.001","article-title":"Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors.","volume":"2","author":"Smith","year":"2008;","journal-title":"J Am Soc Hypertens"},{"key":"key20250623065138_B70","unstructured":"Brignole Michele. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers; e-Journal of Cardiology Practice. 2005;4(12). https:\/\/www.escardio.org\/Journals\/E-Journal-of-Cardiology-Practice\/Volume-4\/vol4n12-Title-Prevention-of-Atrial-Fibrillation-with-Angiotensin-Converting-E. Accessed 27 Aug 2024."},{"issue":"(6):","key":"key20250623065138_B71","first-page":"475\u2013","article-title":"Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials.","volume":"29","author":"Zhao","year":"2015;","journal-title":"J Biomed Res"},{"issue":"(20):","key":"key20250623065138_B72","doi-asserted-by":"crossref","first-page":"e3721.","DOI":"10.1097\/MD.0000000000003721","article-title":"Angiotensin-receptor blocker, angiotensin-converting enzyme inhibitor, and risks of atrial fibrillation: a nationwide cohort study.","volume":"95","author":"Hsieh","year":"2016;","journal-title":"Medicine (Baltimore)"},{"key":"key20250623065138_B73","doi-asserted-by":"crossref","first-page":"114\u2013","DOI":"10.1016\/j.ijcard.2016.04.096","article-title":"Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - a real-world population study in Taiwan.","volume":"215:","author":"Pai","year":"2016;","journal-title":"Int J Cardiol"},{"issue":"(8):","key":"key20250623065138_B74","doi-asserted-by":"crossref","first-page":"E148\u2013","DOI":"10.1503\/cmaj.150771","article-title":"Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.","volume":"188","author":"Shih","year":"2016;","journal-title":"CMAJ"},{"issue":"(18):","key":"key20250623065138_B75","doi-asserted-by":"crossref","first-page":"2143\u2013","DOI":"10.4103\/0366-6999.189924","article-title":"Olmesartan reduces new-onset atrial fibrillation and atrial fibrillation burden after dual-chamber pacemaker implantation in atrioventricular block patients.","volume":"129","author":"Zhang","year":"2016;","journal-title":"Chin Med J (Engl)"},{"issue":"(2):","key":"key20250623065138_B76","doi-asserted-by":"crossref","first-page":"e000810.","DOI":"10.1161\/JAHA.114.000810","article-title":"The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.","volume":"3","author":"Menne","year":"2014;","journal-title":"J Am Heart Assoc"},{"issue":"(10304):","key":"key20250623065138_B77","first-page":"957\u2013","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC).","year":"2021;","journal-title":"Lancet"},{"key":"key20250623065138_B78","doi-asserted-by":"crossref","first-page":"100113.","DOI":"10.1016\/j.lansea.2022.100113","article-title":"Hypertension control rate in India: systematic review and meta-analysis of population-level non-interventional studies, 2001-2022.","volume":"9:","author":"Koya","year":"2022;","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"(2):","key":"key20250623065138_B79","doi-asserted-by":"crossref","first-page":"109\u2013","DOI":"10.1007\/s40292-023-00563-8","article-title":"Single-pill combination with three antihypertensive agents to improve blood pressure control in hypertension: focus on olmesartan-based combinations.","volume":"30","author":"Burnier","year":"2023;","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"(2):","key":"key20250623065138_B80","doi-asserted-by":"crossref","first-page":"51\u2013","DOI":"10.1177\/8755122518809005","article-title":"Amlodipine-induced pedal edema and its relation to other variables in patients at a tertiary level hospital of Kathmandu, Nepal.","volume":"35","author":"Khadka","year":"2019;","journal-title":"J Pharm Technol"},{"issue":"(3):","key":"key20250623065138_B81","first-page":"299\u2013","article-title":"Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.","volume":"3","author":"Kjeldsen","year":"2007;","journal-title":"Vasc Health Risk Manag"},{"issue":"(1):","key":"key20250623065138_B82","doi-asserted-by":"crossref","first-page":"5\u2013","DOI":"10.1111\/jch.14700","article-title":"Efficacy and safety of olmesartan medoxomil-amlodipine besylate tablet in Chinese patients with essential hypertension: a prospective, single-arm, multi-center, real-world study.","volume":"26","author":"Cui","year":"2024;","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"(2):","key":"key20250623065138_B83","doi-asserted-by":"crossref","first-page":"51.","DOI":"10.3892\/etm.2023.12338","article-title":"Efficacy and safety of olmesartan medoxomil\u2013amlodipine besylate tablets (Sevikar\u00ae) in older patients with essential hypertension: subgroup analysis from the Sevikar study.","volume":"27","author":"Cui","year":"2023;","journal-title":"Exp Ther Med"},{"issue":"(12):","key":"key20250623065138_B84","doi-asserted-by":"crossref","first-page":"1086\u2013","DOI":"10.1007\/s12325-013-0076-6","article-title":"The fixed-dose combination of olmesartan\/amlodipine was superior in central aortic blood pressure reduction compared with perindopril\/amlodipine: a randomized, double-blind trial in patients with hypertension.","volume":"30","author":"Ruilope","year":"2013;","journal-title":"Adv Ther"},{"issue":"(11):","key":"key20250623065138_B85","doi-asserted-by":"crossref","first-page":"2083\u2013","DOI":"10.1097\/01.hjh.0000186022.74245.01","article-title":"Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.","volume":"23","author":"Sellin","year":"2005;","journal-title":"J Hypertens"},{"issue":"(11):","key":"key20250623065138_B86","doi-asserted-by":"crossref","first-page":"4817\u2013","DOI":"10.1007\/s12325-023-02632-9","article-title":"Real-world effectiveness and safety of a single-pill combination of olmesartan\/amlodipine\/hydrochlorothiazide in Korean patients with hypertension and cardiovascular risk factors.","volume":"40","author":"Oh","year":"2023;","journal-title":"Adv Ther"},{"issue":"(1):","key":"key20250623065138_B87","doi-asserted-by":"crossref","first-page":"21.","DOI":"10.1186\/s40885-021-00177-z","article-title":"Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO).","volume":"27","author":"Sohn","year":"2021;","journal-title":"Clin Hypertens"},{"issue":"(10):","key":"key20250623065138_B88","doi-asserted-by":"crossref","first-page":"649\u2013","DOI":"10.1007\/BF03261919","article-title":"Efficacy and safety of triple antihypertensive therapy with the olmesartan\/amlodipine\/hydrochlorothiazide combination.","volume":"32","author":"Volpe","year":"2012;","journal-title":"Clin Drug Investig"},{"issue":"(6):","key":"key20250623065138_B89","doi-asserted-by":"crossref","first-page":"404\u2013","DOI":"10.1111\/j.1751-7176.2011.00437.x","article-title":"A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil \u00b1 hydrochlorothiazide.","volume":"13","author":"Weir","year":"2011;","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"(7):","key":"key20250623065138_B90","doi-asserted-by":"crossref","first-page":"1252\u2013","DOI":"10.1016\/j.clinthera.2010.07.008","article-title":"Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.","volume":"32","author":"Oparil","year":"2010;","journal-title":"Clin Ther"},{"issue":"(12):","key":"key20250623065138_B91","doi-asserted-by":"crossref","first-page":"2978\u2013","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.","volume":"54","author":"Imai","year":"2011;","journal-title":"Diabetologia"},{"key":"key20250623065138_B92","unstructured":"USFDA. Drug Safety Communication 2014: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-review-cardiovascular-risks-diabetics-taking-hypertension-drug. Accessed 21 Jul 2024."},{"key":"key20250623065138_B93","unstructured":"USFDA Drug Safety Communication 2014. https:\/\/wayback.archive-it.org\/7993\/20170113112059\/http:\/www.fda.gov\/downloads\/. USFDA Drug Safety Communication 2014. https:\/\/wayback.archive-it.org\/7993\/20170113112059\/http:\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM402339.pdf. Accessed 21 Jul 2024."},{"issue":"(4):","key":"key20250623065138_B94","doi-asserted-by":"crossref","first-page":"348\u2013","DOI":"10.1002\/pds.3558","article-title":"Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.","volume":"23","author":"Walker","year":"2014;","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"(10):","key":"key20250623065138_B95","doi-asserted-by":"crossref","first-page":"1578\u2013","DOI":"10.1097\/HJH.0000000000003509","article-title":"Safety and cardiovascular effectiveness of olmesartan in combination therapy for advanced hypertension: an electronic health record-based cohort study.","volume":"41","author":"Kim","year":"2023;","journal-title":"J Hypertens"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T06:51:57Z","timestamp":1750661517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-72-12-59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":95,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.59556\/japi.72.0780"],"URL":"https:\/\/doi.org\/10.59556\/japi.72.0780","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}